Michael McCaughan, co-founder of Provision Policy, spoke about drug pricing policy at the 340B Coalition Winter Conference.
Potential Senate Flip May Increase 340B Scrutiny, But Congressional 340B Action Unlikely in 2024, Say 340B Advocate, Drug Industry Analyst
Views
Congress is unlikely to act on 340B in 2024, but a potential flip of the U.S. Senate could lead to [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
